In breast cancer CA 15.3 is considered the tumour marker of choice. CA 15.3 is directly related to the disease extent and to hormone status (estrogen receptor ER+/ ER-, progesterone receptor PR+/PR-). This study was designed to assess the impact of disease extent, hormone receptor and HER2-status, and circulating blood volume on the area-under the ROC-curve of CA 15.3 to separate FDG PET positive from negative findings. Patients, methods: We retrospectively evaluated 379 FDG PET/CT examinations performed in 80 patients with breast cancer. Blood volumes were derived using the formulas by Nadler and multiplied by their corresponding CA 15.3 measurement. Results: ROC-curve analysis revealed an AUC of 0.695 (p = 0.0001) for CA 15.3 to separate FDG PET positive from negative findings. AUC measurements to separate normal scan findings from loco-regional disease and metastatic disease were 0.527 (p = 0.587) and 0.732 (p = 0.0001), respectively. AUC measurements for CA 15.3 to separate positive from negative FDG PET findings, in ER+ and ER-patients, were respectively 0.772 (p = 0.0001) and 0.596 (p = 0.143). AUC measurements for CA 15.3 to separate positive from negative FDG PET findings, in PR+ and PRpatients, were respectively 0.675 (p = 0.0001) and 0.694 (p = 0.0001). In HER2-positive and -negative patients, the AUC measurements were respectively 0.594 (p = 0.178) and 0.701 (p = 0.0001) to separate positive from negative FDG PET findings. Conclusion: The AUC for CA 15.3 measurements to separate FDG PET positive from negative findings in breast cancer patients with suspected recurrence proved to be directly related to the extent of the recurrent disease and hormone receptor status and inversely related to HER2-status. Correcting CA15.3 measurements for blood volumes did not impact the AUC. 
Summary
In breast cancer CA 15.3 is considered the tumour marker of choice. CA 15.3 is directly related to the disease extent and to hormone status (estrogen receptor ER+/ ER-, progesterone receptor PR+/PR-). This study was designed to assess the impact of disease extent, hormone receptor and HER2-status, and circulating blood volume on the area-under the ROC-curve of CA 15.3 to separate FDG PET positive from negative findings. Patients, methods: We retrospectively evaluated 379 FDG PET/CT examinations performed in 80 patients with breast cancer. Blood volumes were derived using the formulas by Nadler and multiplied by their corresponding CA 15.3 measurement. Results: ROC-curve analysis revealed an AUC of 0.695 (p = 0.0001) for CA 15.3 to separate FDG PET positive from negative findings. AUC measurements to separate normal scan findings from loco-regional disease and metastatic disease were 0.527 (p = 0.587) and 0.732 (p = 0.0001), respectively. AUC measurements for CA 15.3 to separate positive from negative FDG PET findings, in ER+ and ER-patients, were respectively 0.772 (p = 0.0001) and 0.596 (p = 0.143). AUC measurements for CA 15.3 to separate positive from negative FDG PET findings, in PR+ and PRpatients, were respectively 0.675 (p = 0.0001) and 0.694 (p = 0.0001). In HER2-positive and -negative patients, the AUC measurements were respectively 0.594 (p = 0.178) and 0.701 (p = 0.0001) to separate positive from negative FDG PET findings. Conclusion: The AUC for CA 15.3 measurements to separate FDG PET positive from negative findings in breast cancer patients with suspected recurrence proved to be directly related to the extent of the recurrent disease and hormone receptor status and inversely related to HER2-status. Correcting CA15.3 measurements for blood volumes did not impact the AUC.
In breast cancer, Cancer Antigen 15.3 (CA 15.3) is considered the serum tumor marker of choice (18) . CA 15-3 is an epitope of a large trans-membrane glycoprotein named MUC1 that is derived from the MUC1 gene. Two possible mechanisms have been proposed to account for its production.
• The extracellular domain of MUC1 can be released into serum via proteolytic cleavage.
• Translation products of the MUC-1 gene have been described that lack the trans-membrane and cytoplasmic domain as well as the proteolytic cleavage site that may be directly secreted from the cell, MUC-1/SEC (17, 23) .
Following curative treatment for breast cancer, limited data suggest that regular serum measurements of CA 15.3 may provide a lead-time of 2-9 months for early recurrence detection (5, 7) . Accordingly, in many centres worldwide, serial measurements of CA 15.3 are part of the routine follow-up of breast cancer patients. However, CA 15.3 serum measurements lack specificity and do not predict the number and location of recurrent disease (12) . Thus, in clinical practice, CA 15.3 serum measurements are being complemented by conventional morphological imaging or since recently by FDG PET/CT imaging. FDG PET/CT imaging which was shown to have an overall pooled accuracy of 83% for breast cancer recurrence detection when a CA 15.3 increase is found (8) . While CA 15.3 levels have proven systematically higher in PET positive versus PET negative patients, to date no single cut-off value yielding an acceptable accuracy to base the prescription of an FDG PET/CT examination on has been identified. Using various cut-off levels for CA 15.3, sensitivities for FDG PET/CT imaging for breast cancer recurrence detection ranging from 75-96% and specificities ranging from 50-100% have been reported (3, 10, 16, 20) .
Of interest, CA 15.3 levels have proven directly related to the disease extent (locoregional versus metastatic) and increases are more pronounced and more frequent in hormone receptor positive patients as opposed to hormone receptor negative patients (17, 22, 23) . Also, for similar sized breast lesions producing similar amounts of soluble MUC-1 in different patients, different CA 15.3 measurements may be obtained due to differences in blood volume; smaller blood volumes will yield higher CA 15.3 measurements. Thus, the aims of this study were to assess the impact of disease extent (loco-regional versus metastatic), hormone receptor status and circulating blood volume on the area-under the ROCcurve of CA 15.3 serum levels for separating FDG PET positive from FDG PET negative findings in breast cancer patients. 
Patients and methods

FDG PET-CT imaging
FDG PET-CT examinations were performed on a dedicated BGO PET system with a helical CT (discovery ST; GE Medical Systems, Milwaukee, WI, USA). Whole body images (from the base of the skull to the proximal third of the femora) were acquired 60 minutes following the injection of FDG. The dose injected per patient was defined using the following formula (body weight-10) x 3 MBq with a minimum activity of 180 MBq and a maximum activity of 300 MBq. Images were reconstructed using an ordered subset expectation maxi- 
Image interpretation
Two experienced nuclear medicine physicians visually evaluated reconstructed images and in case of discrepancy (none) a final diagnosis was reached by consensus. Any non-physiological, increased FDG uptake with either highly suspicious or definite morphological changes was considered as pathological. The absence of FDG uptake aside from normal physiological uptake was considered as a negative FDG-PET-CT examination.
Follow-up
In all patients, a conclusive diagnosis was obtained from the results of histopathological examination or from clinical/imaging follow-up. Fig. 1 ). The AUC in ER-negative patients proved significantly smaller when compared to that obtained in ER-positive patients (p = 0.01) (▶ Fig. 3) . CA 15.3 levels measured in PR-positive breast carcinoma proved significantly higher compared to those obtained in PRnegative breast carcinoma ((n=192) : 93 IU/ml (range: 0-1100 IU/ml) versus (n=106) : 53 IU/ml (range: 8-708 IU/ml) (p = 0.006)) (▶ Fig. 4a) . AUCs under the curve for CA 15.3 to separate positive from negative FDG PET-CT scan findings, in PR-positive and PR-negative patients were Fig. 4b, ▶ Fig. 4c ). CA 15.3 levels measured in HER2-positive breast carcinoma proved not significantly different from those obtained in HER2-negative breast carcinoma ((n= 304)
Locoregional versus metastatic disease
: 108 IU/ml (range: 0-2240 IU, /ml) versus (n=75) : 86 IU/ml (range: 12-708 IU/ml) (p=0.465)). AUC's under the curve for CA 15.3 to separate positive from negative FDG PET-CT scan findings, in HER2-positive and negative patients were respectively 0.594 (p = 0.178) and 0.701 (p = 0.0001) (▶ Fig. 5 ). The AUC in HER2-negative patients proved significantly higher compared to that obtained in HER2positive patients (p = 0.01).
Blood volume corrected CA 15.3 measurements
Mean blood volume was 4.0 l (range: 2.6-6.0 l; SD: 0.6 l). Blood-volume cor- (22). While in the series presented, CA 15.3 levels proved not significantly different between estrogen-receptor positive and estrogen-receptor negative patients, the AUC value for CA 15.3 to separate positive from negative FDG PET-CT findings in estrogen-receptor positive patients proved significantly higher when compared to that obtained in estrogen-receptor negative patients (0.772 versus 0.596; p = 0.01). In the breast cancer cell lines MCF-7 and T47D, MUC-1/SEC was shown to be dependent on estrogen expression; the estrogen receptor alpha could bind estrogen response elements (EREs) that are present in the MUC-1 promotor. In turn, MUC-1 was shown to activate and stabilize ER-á by binding to the DNA-binding domain of the receptor enhancing its activation. Furthermore, MUC1 was shown to promote estradiol mediated growth and survival of breast cancer cells (4) . In line with these preclinical findings, Park et al. showed in a series of 707 patients who were diagnosed with metastatic or recurrent breast cancer that supranormal levels of CA 15.3 are more frequently observed in hormone receptor positive patients, estrogen receptor positive and/or progesterone receptor positive (16). Bensouda et al. reported similar findings in a series of 272 patients in whom CA 15.3 was increased in 168 patients at diagnosis of metastases and found to be elevated in 69% of hormone receptor positive patients versus 46 % of hormone receptor negative patients (2). The close biological link between the secretion and serum levels of MUC-1, from which the CA 15.3 epitope is derived, and estrogen receptor status as suggested by these studies is in line with the higher AUC found in estrogen receptor positive patients including 1050 normal control subjects, 9.4% of normal controls had CA 15.3 levels greater than 22 U/ml while that from 5.5% and 1.3% had levels greater than 25 U/ml and 30 U/ml. Inversely, only 13 of 26 patients presenting with loco-regional disease had CA 15.3 levels greater than 22 U/ml (13) . Finally, in a series by Stieber et al. including 272 apparently healthy individuals, 34 pregnant women, 308 benign diseases, 273 cancers other than breast cancer and 439 breast cancer patients, 12% of patients presenting with benign breast disease had CA 15.3 levels ≥ 25 IU/ml (21) . On the other hand, small clusters of tumoral cells may be missed by FDG PET imaging due to the relatively poor spatial resolution of this imaging modality, around 5-6 mm, and related partial volume effects (11) . Inversely, in patients presenting with metastatic disease (with or without associated loco-regional involvement) on FDG PET-CT imaging, CA 15.3 values proved significantly higher when compared to patients with normal scan findings or presenting with locoregional disease; using a cut-off value of 34.2 IU/ml for CA 15.3, a sensitivity and specificity for separating normal scan findings from positive scan findings of both 69% were obtained. Again, this finding is in line with previous data, respectively reported by Gerachty et al. and Colomor et al. (6, 9) . In the study by Gerachty et al. 22 
Discussion
In the series presented, mean CA 15.3 levels in patients presenting with normal scan findings or presenting with loco-regional disease proved not significantly different from each other. The area under the CA 15.3 ROC-curve for separating normal scan findings from locoregional disease was 0.527 (p = 0.587) suggesting CA 15.3 is neither a sensitive nor specific biomarker for predicting loco-regional recurrence. Previous studies have already shown that serum CA 15.3 levels in patients with localised breast cancer largely overlap those found in healthy women or women with benign breast disease (15). Geraghty et al. studied 129 patients presenting with recurrent breast carcinoma. Out of 14 patients with isolated loco-regional disease, only one patient had increased levels of CA 15.3 (> 25 IU/ml) (9) . In a series by Hayes et al. when compared to estrogen receptor negative patients is not surprising. While expression of the progesterone receptor expression also requires a functional estrogen receptor, similar to MUC-1, in this series, it's absence or presence did not significantly impact the AUC for CA 15.3 suggesting different pathways may be involved regulating their transcription. Of interest, the AUC in HER2-negative patients proved significantly higher when compared to that obtained in HER2-positive patients (0.701 versus 0.594 (p = 0.01). The inverse relationship between HER2 over-expression and estrogen or progesterone receptor expression is well known (1, 14, 19) . While ER and PR are not an independent predictor for the HER2-status in young women, they are in patients older than 45 years of age (4) . In the series presented, the mean age of the patients at the time of diagnosis was 51.4 years, thus the good AUC found in HER2-negative patients in our series is most likely a reflection of the predominant ER-positive status of these patients.
Finally, for similar sized breast lesions producing similar amounts of CA 15.3 in different patients, different CA 15.3 measurements may be obtained due to differences in circulating blood volume; smaller blood volumes are likely to yield higher CA 15.3 measurements.
Limitations
When performing ROC analysis, ideally one imaging episode/patient should be included in order to avoid too high an impact of a single individual on the area-under the curve. In the series presented, we included several PET-CT imaging data sets per patient. However, as this was the case for all patients included (on average 5 PET-CT examinations per patient) and imaging data sets were acquired over a large period of time, reflecting various clinical situations in one patient, it is unlikely that cutoff values defined in the series presented are impacted significantly by single individuals included in the study. Furthermore, cut-off values identified are similar to those previously reported in the literature.
Conclusion
In this series, the AUC for CA 15.3 measurements to separate FDG PET/CT positive from negative findings in breast cancer patients in whom a recurrence was suspected proved to be directly related to the extent of the recurrent disease (loco-regional versus metastatic disease) and hormone receptor status (ER + versus ER -) and inversely related to HER2 status. The wide variability reported in literature in terms of sensitivity and specificity for identifying breast cancer recurrence using various cut-offs of CA 15.3 to guide FDG PET/ CT imaging may thus in part be explained by differences in proportions of such patients being included. Correcting CA15.3 measurements for blood volumes did not impact the AUC.
